MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - Dec 17, 2012) - MorphoSys AG /
MorphoSys to Host Conference Call on Bio-Rad's planned Acquisition of
MorphoSys's Research and Diagnostic Antibody Business AbD Serotec.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Today at 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EST), the Management Board
MorphoSys AG will host a public conference call and webcast to present
information on Bio-Rad's planned acquisition of MorphoSys's research and
diagnostic antibody business AbD Serotec.
Dial-in numbers for the Conference Call (listen-only):
Germany: +49 (0) 89 2444 32975
For U.K. residents: +44 (0) 20 3003 2666
For U.S. residents: +1 202 204 1514
MorphoSys offers participants the opportunity to follow the presentation
a simultaneous slide presentation online at http://www.morphosys.com.
An audio replay and manuscripts of the conference will be
www.morphosys.com/conference-calls in due course.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
Ylanthia® and 100 billion high potentials® are registered
Slonomics® is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Conference Call Alert (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE